Physician profile
Doris Chan
NPI 1508109943
$3,968.17
in general payments reported to CMS, 2019-2025
20 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $873 · 2021: $960 · 2022: $1,293 · 2023: $414 · 2024: $309 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $710.63 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $639.97 | 2020-2024 | |
| Medtronic, INC. | $577.21 | 2021-2022 | |
| Shockwave Medical, INC | $451.29 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Bard Peripheral Vascular, INC. | $358.45 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $187.52 | 2022-2024 | |
| Abiomed | $180.83 | 2020 | |
| Philips North America LLC | $123.00 | 2020-2025 | Ecc Solutions, (Ck4) Mcot |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.12 | 2022-2023 | Trulance |
| Esperion Therapeutics, INC. | $91.53 | 2021 | |
| Abbvie INC. | $91.37 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.56 | 2021-2023 | Jardiance |
| Cardiovascular Systems INC. | $77.70 | 2020 | |
| Saranas, INC. | $72.49 | 2022 | |
| Amarin Pharma, INC. | $69.48 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $48.42 | 2022-2023 | Dragonfly Opstar |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.19 | 2020 | |
| Arbor Pharmaceuticals, INC. | $30.84 | 2021 | |
| Penumbra, INC. | $20.00 | 2022 | |
| Lilly USA, LLC | $18.57 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.